药学学报, 2022, 57(3): 695-699
引用本文:
耿晶, 杨跃梅, 李新颖. 新型靶向HER2抗体MIL40偶联药物的抗肿瘤活性研究[J]. 药学学报, 2022, 57(3): 695-699.
GENG Jing, YANG Yue-mei, LI Xin-ying. Anti-tumor activity of novel targeting HER2 antibody-drug conjugates[J]. Acta Pharmaceutica Sinica, 2022, 57(3): 695-699.

新型靶向HER2抗体MIL40偶联药物的抗肿瘤活性研究
耿晶1, 杨跃梅2, 李新颖3*
1. 中国医学科学院医药生物技术研究所, 北京 100050;
2. 北京瑷格干细胞科技有限公司, 北京 102604;
3. 军事医学研究院军事认知与脑科学研究所, 北京 100850
摘要:
抗体偶联药物(antibody-drug conjugates,ADCs)目前已被广泛应用于肿瘤治疗。人表皮生长因子受体2 (human epidermal growth factor receptor 2,HER2)在包括乳腺癌、胃癌和卵巢癌在内的多种实体瘤中均呈特异性高表达,被视为理想的肿瘤治疗靶点。本研究在一种靶向HER2的新型抗体—MIL40的基础上,成功构建靶向HER2的ADCs (MIL40-DM1和MIL40-MMAE),并研究其抗肿瘤活性。实验结果表明,MIL40-DM1和MIL40-MMAE能够有效识别并结合HER2阳性肿瘤细胞。偶联DM1和MMAE后,MIL40-DM1和MIL40-MMAE与HER2-ECD抗原的结合能力并未受到影响。两者在体外均能有效杀伤HER2阳性SKOV3卵巢癌细胞、SKBR3乳腺癌细胞和N87胃癌细胞。MIL40-DM1能够有效抑制小鼠SKOV3移植瘤的体积以及重量的增长(本研究中的小鼠按照国际实验室动物护理和使用准则进行使用和治疗,并得到了军事医学科学院军事认知与脑科学研究所动物伦理委员会的批准)。
关键词:    人表皮生长因子受体2      肿瘤靶向治疗      抗体-药物偶联物      DM1      MMAE     
Anti-tumor activity of novel targeting HER2 antibody-drug conjugates
GENG Jing1, YANG Yue-mei2, LI Xin-ying3*
1. Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2. Beijing Aegle Stem Technology Co., Ltd., Beijing 102604, China;
3. Institute of Military Cognition and Brain Sciences, Academy of Military Medical Sciences, Beijing 100850, China
Abstract:
Antibody-drug conjugates (ADCs) are widely used in cancer treatment. Human epidermal growth factor receptor-2 (HER2) is overexpressed in various types of solid tumors and is a validated therapeutic target for cancers. To develop a more effective therapy, we generated a novel anti-HER2 humanized monoclonal antibody MIL40 and MIL40 drug conjugates as novel cancer therapies. The MIL40 was conjugated with small molecule cytotoxic agents DM1 [emtansine, N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine] or monomethylauristatin E (MMAE) to generate ADCs, which were evaluated for their in vitro and in vivo anti-cancer activities. Experimental results show that MIL40-DM1 and MIL40-MMAE can effectively identify and bind to HER2-positive tumor cells. The binding capabilities of MIL40-DM1 and MIL40-MMAE with HER2 extracellular domain (ECD) antigens were not different after conjugation with DM1 or MMAE. The ADCs showed potent cytotoxicity in HER2-positive ovarian cancer cells SKOV3, breast cancer cells SKBR3 and stomach cancer cells N87 in vitro. MIL40-DM1 can effectively inhibit the volume and weight growth of SKOV3 transplant tumors in mice. The mice in this study were used and treated by following the international guidelines for the care and use of laboratory animals, and approved by Animal Ethics Committee of Institute of Military Cognitive and Brain Sciences.
Key words:    Key words: human epidermal growth factor receptor 2    tumor targeting therapy    antibody-drug conjugate    DM1    MMAE   
收稿日期: 2021-05-25
DOI: 10.16438/j.0513-4870.2021-0789
基金项目: 中国医学科学院医学与健康科技创新工程项目(2021-I2M-1-026)。
通讯作者: 李新颖,Tel:86-10-66931325,E-mail:lychee526@163.com
Email: lychee526@163.com
相关功能
PDF(1165KB) Free
打印本文
0
作者相关文章
耿晶  在本刊中的所有文章
杨跃梅  在本刊中的所有文章
李新颖  在本刊中的所有文章

参考文献:
[1] Moasser MM. The oncogene HER2:its signaling and transforming functions and its role in human cancer pathogenesis[J]. Oncogene, 2007, 26:6469-6487.
[2] Iqbal N, Iqbal N. Human epidermal growth factor receptor 2(HER2) in cancers:overexpression and therapeutic implications[J]. Mol Biol Int, 2014, 2014:852748.
[3] Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers:review of results from 37, 992 patients[J]. Cancer Metastasis Rev, 2015, 34:157-164.
[4] Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates[J]. Nat Rev Drug Discov, 2017, 16:315-337.
[5] Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing:is antigen-dependent internalisation required?[J]. Br J Cancer, 2017, 117:1736-1742.
[6] Lambert JM, Chari RV. Ado-trastuzumab emtansine (T-DM1); an antibody-drug conjugate (ADC) for HER2-positive breast cancer[J]. J Med Chem, 2014, 57:6949-6964.
[7] Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma[J]. Nat Biotechnol, 2012, 30:631-637.
[8] McGregor BA, Sonpavde G. Enfortumab vedotin, a fully human monoclonal antibody against nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial carcinoma[J]. Expert Opin Investig Drugs, 2019, 28:821-826.
[9] Norsworthy KJ, Ko CW, Lee JE, et al. FDA approval summary:mylotarg for treatment of patients with relapsed or refractory CD33-positive acute myeloid leukemia[J]. Oncologist, 2018, 23:1103-1108.
[10] Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia[J]. N Engl J Med, 2016, 375:740-753.
[11] Nakada T, Sugihara K, Jikoh T, et al. The latest research and development into the antibody-drug conjugate,[fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy[J]. Chem Pharm Bull (Tokyo), 2019, 67:173-185.
[12] Chari RV. Targeted cancer therapy:conferring specificity to cytotoxic drugs[J]. Acc Chem Res, 2008, 41:98-107.
[13] Doronina SO, Toki BE, Torgov MY, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy[J]. Nat Biotechnol, 2003, 21:778-784.
[14] Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer[J]. N Engl J Med, 2012, 367:1783-1791.
[15] Elsada A, Doss S, Robertson J, et al. NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer[J]. Lancet Oncol, 2016, 17:143-144.
[16] Hunter FW, Barker HR, Lipert B, et al. Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer[J]. Br J Cancer, 2020, 122:603-612.
[17] de Claro RA, McGinn K, Kwitkowski V, et al. U.S. Food and Drug Administration approval summary:brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma[J]. Clin Cancer Res, 2012, 18:5845-5849.
[18] Richardson NC, Kasamon YL, Chen H, et al. FDA approval summary:brentuximab vedotin in first-line treatment of peripheral T-cell lymphoma[J]. Oncologist, 2019, 24:e180-e187.
[19] LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine:a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer[J]. Clin Cancer Res, 2011, 17:6437-6447.
[20] Yu Q, Yuan JL, Zhai XT, et al. Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM[J]. Acta Pharm Sin (药学学报), 2021, 56:496-502.